Charles River Laboratories Intl. Inc vs Teucrium Soybean Fund — how do they compare? Charles River Laboratories Intl. Inc trades at $302.69 (market cap $14.23B), while Teucrium Soybean Fund trades at $27.15 (market cap $43.52M). The key difference: Charles River Laboratories Intl. Inc is far larger — about 327× Teucrium Soybean Fund's market cap, and Teucrium Soybean Fund is more actively traded (32,585 versus 1,176,885). Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Teucrium Soybean Fund for 23 Days on average.
| CRL | SOYB | |
|---|---|---|
Market Cap | $14.23B | $43.52M |
Volume | 1,176,885 | 32,585 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $310.77 | $28.14 |
52-Week Low | $149.93 | $21.55 |
Typical Hold Time | 33 Days | 23 Days |
Enterprise Value | $17.06B | — |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $300.53, up 0.08% on the day, with a bullish technical outlook and strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, though it faces profitability challenges with a negative net income margin and ROE. Recent investor day presentations highlighted a strategic plan targeting 5-7% revenue growth and $300 million in savings by 2030, driving positive sentiment.
The outlook is cautiously optimistic, supported by analyst buy ratings and a $305.50 consensus price target, but risks include ongoing margin pressure, volatile non-human primate costs, and a high valuation multiple. Earnings growth and successful execution of the new strategic plan are critical for sustained upside.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →SOYB is a commodity ETF that provides exposure to the price of soybean futures. It utilizes a laddered strategy by investing in several benchmark futures contracts to reduce the impact of roll costs and contango in the agricultural market.
Read more on SOYB →